Published Research
Sunstone leads and supports FDA-approved clinical trials in collaboration with top-tier research sponsors, academic institutions, and healthcare systems. Our studies cover a diverse set of psychedelic compounds and mental health indications, including trauma-related disorders, mood conditions, and end-of-life distress.
01
Sunstone designs and delivers innovative clinical trials with leading psychedelic drug developers and medical bodies.
- atai Life Sciences
- Beckley Psytech
- Compass Pathways
- Cybin
- Resilient Pharmaceuticals
- Reunion Neuroscience
- Transcend Therapeutics
- Usona Institute
02
We work with a broad range of psychedelics.
- Psilocybin & Analogs
- MDMA & Analogs
- LSD & Analogs
- 5-MeO-DMT & Analogs
- Methylone & Analogs
03
Across a wide array of clinical indications.
- Adjustment Disorder (AD)
- Advanced Illness
- Generalized Anxiety Disorder (GAD)
- Major Depressive Disorder (MDD)
- Major Depressive Disorder in Patients with Cancer
- Post-Traumatic Stress Disorder (PTSD)
- Postpartum Depression
- Treatment-Resistant Depression (TRD)
04
In partnership with top-tier academic and medical institutions.
- Adventist HealthCare
- Dana-Farber Cancer Institute
- Johns Hopkins Center for Psychedelic & Consciousness Research
- McGill University
- Memorial Sloan Kettering Cancer Center
- The University of Vermont
Sunstone Published Research
Explore our growing list of published research featured in medical journals and publications.
-
Rosa, W.E., Napolitano, S., McAndrew, N.S., Jenkins, B., et al. “Meaning-centered psychotherapy for psilocybin-assisted therapy among patients with advanced cancer and major depression: Rationale and preliminary evaluation of MCP-PSIL.” Psychedelic Medicine, August 2025.
Read More: Rosa, W.E., Napolitano, S., McAndrew, N.S., Jenkins, B., et al. “Meaning-centered psychotherapy for psilocybin-assisted therapy among patients with advanced cancer and major depression: Rationale and preliminary evaluation of MCP-PSIL.” Psychedelic Medicine, August 2025.
-
Agrawal M., Emanuel E., Jenkins B., et al. “Long-term Benefits of Single-Dose Psilocybin in Depressed Cancer Patients.” Cancer, June 2025.
Read More: Agrawal M., Emanuel E., Jenkins B., et al. “Long-term Benefits of Single-Dose Psilocybin in Depressed Cancer Patients.” Cancer, June 2025.
-
Davis A., Bates M., Koffman R., et al. “The Epidemiology of Psychedelic Use Among United States Military Veterans.” Journal of Psychoactive Drugs, Sep 2024.
Read More: Davis A., Bates M., Koffman R., et al. “The Epidemiology of Psychedelic Use Among United States Military Veterans.” Journal of Psychoactive Drugs, Sep 2024.
-
Ehrenkranz R., Agrawal M., Nayak S., Yaden., D. “Adverse Events Should Not Be Surprising in Psychedelic Research.” Psychedelic Medicine, September 2024.
Read More: Ehrenkranz R., Agrawal M., Nayak S., Yaden., D. “Adverse Events Should Not Be Surprising in Psychedelic Research.” Psychedelic Medicine, September 2024.
-
Ehrenkranz R., Agrawal M., Penberthy J., Yaden., D. “Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder.” International Review of Psychiatry, May 2024.
Read More: Ehrenkranz R., Agrawal M., Penberthy J., Yaden., D. “Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder.” International Review of Psychiatry, May 2024.
-
Beaussant Y., Tarbi E., Nigam K., et al. “Acceptability of psilocybin-assisted group therapy in patients with cancer and MDD.” Cancer, Dec 2023.
Read More: Beaussant Y., Tarbi E., Nigam K., et al. “Acceptability of psilocybin-assisted group therapy in patients with cancer and MDD.” Cancer, Dec 2023.
-
Marseille E., Stauffer C., Agrawal M., et al. “Group psychedelic therapy: empirical estimates of cost-savings and improved access.” Front. Psychiatry, Dec. 2023.
Read More: Marseille E., Stauffer C., Agrawal M., et al. “Group psychedelic therapy: empirical estimates of cost-savings and improved access.” Front. Psychiatry, Dec. 2023.
-
Gramling R., Bennett E., Curtis K., et al. “Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study.” J Palliat Med, Aug. 2023.
Read More: Gramling R., Bennett E., Curtis K., et al. “Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study.” J Palliat Med, Aug. 2023.
-
Agrawal M., Richards W., Beaussant Y., et al. “Psilocybin‐assisted group therapy in patients with cancer diagnosed with a major depressive disorder.” Cancer, July 2023.
Read More: Agrawal M., Richards W., Beaussant Y., et al. “Psilocybin‐assisted group therapy in patients with cancer diagnosed with a major depressive disorder.” Cancer, July 2023.
-
Agrawal M., Emanuel E., Richards B., et al. “Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder.” JAMA Oncology, April 2023.
Read More: Agrawal M., Emanuel E., Richards B., et al. “Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder.” JAMA Oncology, April 2023.
-
Shnayder S., Amelia R., Sinai., Berger A., Agrawal M. “Psilocybin-assisted therapy improves psycho-social-well-being in cancer patients.” Journal of Affective Disorders, Dec 2022.
Read More: Shnayder S., Amelia R., Sinai., Berger A., Agrawal M. “Psilocybin-assisted therapy improves psycho-social-well-being in cancer patients.” Journal of Affective Disorders, Dec 2022.
-
Agrawal M., Thambi P., Shnayder S. “The Safety and Efficacy Of Psilocybin Therapy in Patients with Cancer and Major Depressive Disorder” Journal of Clinical Oncology, June 2022.
Read More: Agrawal M., Thambi P., Shnayder S. “The Safety and Efficacy Of Psilocybin Therapy in Patients with Cancer and Major Depressive Disorder” Journal of Clinical Oncology, June 2022.
-
Carhart-Harris, R. L., Wagner, A. C., Agrawal, M., Kettner, H., Rosenbaum, J. F., Gazzaley, A., Nutt, D. J., & Erritzoe, D. “Can Pragmatic Research, Real-World Data, and Digital Technologies Aid the Development of Psychedelic Medicine?” Journal of Psychopharmacology, Jan 2022.
Read More: Carhart-Harris, R. L., Wagner, A. C., Agrawal, M., Kettner, H., Rosenbaum, J. F., Gazzaley, A., Nutt, D. J., & Erritzoe, D. “Can Pragmatic Research, Real-World Data, and Digital Technologies Aid the Development of Psychedelic Medicine?” Journal of Psychopharmacology, Jan 2022.